GSK4527226 in Early Alzheimer's Disease

Market
100%75%50%25%0%Apr 21 • YES 50.0%Apr 21Apr 21 • YES 29.3%Apr 21Apr 21 • YES 27.9%Apr 21Apr 21 • YES 26.1%Apr 21Apr 21 • YES 23.7%Apr 21Apr 21 • YES 23.7%Apr 21
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
9/30/26
Study Completion
11/23/26
Sponsor
GlaxoSmithKline
$GSK
Type
Phase 2
Trial Status
Active Not Recruiting
Trial Size
367
Volume
$604
NCT
NCT06079190
Trial Description
Phase 2 randomized, double-blind, placebo-controlled, 3-arm multicenter study evaluating intravenous GSK4527226 in participants with early Alzheimer's disease, including MCI and mild dementia due to AD. The study compares two dose levels of GSK4527226 versus placebo, with the primary efficacy endpoint based on change from baseline in CDR-SB across Weeks 52, 64, and 76.